Christian T Ruff MD

Cardiovascular Disease Genetics

Director of General Cardiology, Brigham and Women's Hospital; Senior Investigator, TIMI Study Group; Associate Professor of Medicine, Harvard Medical School

Join to view full profile

75 Francis StBrigham & Women's HospitalBoston, MA 02115
Phone+1 617-732-6660

Dr. Ruff is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ruff's full profile Already have an account?

Education & Training

Mass General Brigham/Brigham and Women's HospitalFellowship, Cardiovascular Disease, 2006 - 2009
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2003 - 2006
Johns Hopkins University School of MedicineClass of 2003

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 2005 - 2028
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Longitudinal Medical Record, Partners Healthcare System, 2013, 2015-2017
CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013, 2015-2017
CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2013, 2015-2017

Publications & Presentations

PubMed

DOAC score among patients receiving Vitamin K antagonists.
Rahul Aggarwal, Christian T Ruff, Michael G Palazzolo, Fionn Cléirigh Büttner, Karen Pieper
American Heart Journal. 2026-11-01
Use of a polygenic risk score to enhance early detection of coronary atherosclerosis.
Milena Petranović, Yi-Pin Lai, Daniel Huck, Arthur Shiyovich, Stephanie A Besser
American Journal of Preventive Cardiology. 2026-10-01
Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in the AZALEA-TIMI 71 study.
Andre M Small, Siddharth M Patel, Robert P Giugliano, David A Morrow, Erica L Goodrich
Blood. 2026-08-06

Journal Articles

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Stephen D Wiviott, Marc S Sabatine, Christian T Ruff, Marc P Bonaca, Deepak L Bhatt, Darren K McGuire, The New England Journal of Medicine
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Erin A Bohula, Stephen D Wiviott, Benjamin M Scirica, Darren K McGuire, Marc S Sabatine, Marc P Bonaca, Christian T Ruff, Silvio E Inzucchi, The New England Journal of Medicine

Lectures

Anticoagulation
2019 ACP Internal Medicine Meeting, Philadelphia - 4/13/2019
Debate: Patient With AF and Atherosclerosis Both an Antiplatelet and Anticoagulant are Needed
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019

Press Mentions

Study Demonstrates Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age, Bleeding RiskMarch 31st, 2025
Fewer Bleeding Events Seen with Abelacimab Than Rivaroxaban in a-fibJanuary 24th, 2025
Study Shows Abelacimab Significantly Reduced Bleeding vs. Standard DOACJanuary 24th, 2025